{"links":{"html":"https://www.erudio.com/reports/eclypse-nct06640166","json":"https://www.erudio.com/reports/eclypse-nct06640166.json","markdown":"https://www.erudio.com/reports/eclypse-nct06640166.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"eclypse-06640166"}},"request":"https://www.erudio.com/contact?report=eclypse-06640166"},"offer":{"cited_commentary_sources":7,"verified_hcp_statements":20,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":11,"optional":true,"price_per_verified_person_usd":15,"price_usd":165,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"eclypse-nct06640166"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=eclypse-06640166","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/eclypse-nct06640166","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-29T02:48:51.327202Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":8,"no_commentary_found":1},"aspects":[{"claim_count":3,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":3,"title":"Primary endpoint: 6-month Progression Free Survival rate"},{"claim_count":4,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":4,"title":"Secondary endpoints"},{"claim_count":6,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":6,"title":"Population and setting"},{"claim_count":6,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":2,"title":"The comparison"},{"claim_count":0,"coverage":"no_commentary_found","id":"T5","registry_field":"outcomesModule","source_count":0,"title":"Safety and tolerability"},{"claim_count":3,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":2,"title":"Design and conduct"},{"claim_count":6,"coverage":"discussed","id":"A1","source_count":2,"title":"Practice adoption and sequencing after first-line targeted therapy plus chemotherapy"},{"claim_count":4,"coverage":"discussed","id":"A2","source_count":3,"title":"Continuation versus rechallenge and the unresolved biological explanation"},{"claim_count":4,"coverage":"discussed","id":"A3","source_count":1,"title":"Conversion therapy and local treatment in selected oligometastatic disease"}],"counts":{"cited_sources":7,"claims_by_expression_type":{"comparison":1,"experience":2,"interpretation":4,"opinion":10,"question":2,"restatement":1},"claims_by_kind":{"attributed_opinion":17,"source_observation":3},"clinician_statements":12,"evidence_units":19,"findings":4,"people_cited":13,"people_identity_verified":11,"people_total":14,"screened_sources":17,"verified_claims":20},"depth":"thin","findings_index":[{"id":"F1","structure":{"claims":5,"claims_by_group":{"comparisons":0,"experience":1,"questions":0,"restated":0,"views":4},"has_counterview":true,"limitations":2,"links":{"context":4,"support":5},"ma_question":true,"named_voices":4,"passages":5,"sources":1,"sources_by_kind":{"commentary":1}},"title":"A concrete sequencing proposal attracts support, but standard-of-care adoption is contested"},{"id":"F2","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":6},"has_counterview":false,"limitations":4,"links":{"context":1,"support":7},"ma_question":true,"named_voices":5,"passages":7,"sources":6,"sources_by_kind":{"commentary":5,"media":1}},"title":"Practice-impact judgments range from a reasonable option to emphatic endorsement"},{"id":"F3","structure":{"claims":4,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":0,"views":2},"has_counterview":false,"limitations":2,"links":{"context":1,"support":4},"ma_question":true,"named_voices":4,"passages":4,"sources":3,"sources_by_kind":{"commentary":3}},"title":"Continuation is favored over rechallenge by one speaker, but the mechanism remains a question"},{"id":"F4","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":1,"questions":0,"restated":0,"views":3},"has_counterview":false,"limitations":2,"links":{"context":1,"support":4},"ma_question":true,"named_voices":4,"passages":4,"sources":1,"sources_by_kind":{"commentary":1}},"title":"The connected treatment discussion preserves a selective local-therapy option"}],"medical_affairs_question":"What comparative evidence would justify a standard-of-care recommendation, and what explains the apparent benefit?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Adoption: a practical proposal, not an agreed standard"},{"id":"section-2","level":2,"title":"How strongly should the signal change practice?"},{"id":"section-3","level":2,"title":"Continuation versus rechallenge: rationale and unanswered mechanism"},{"id":"section-4","level":2,"title":"Local therapy: an exception linked to extent and sites"},{"id":"section-5","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, na, single group, phase2","trial_dimensions":[{"findings":[{"id":"F2","shared_claims":3}],"id":"T1","label":"Primary endpoint: 6-month Progression Free Survival rate"},{"findings":[{"id":"F2","shared_claims":4},{"id":"F3","shared_claims":1}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":4},{"id":"F3","shared_claims":1}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F3","shared_claims":1}],"id":"T4","label":"The comparison"},{"findings":[],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F2","shared_claims":3}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-29T02:48:51.327202Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-29T03:20:05Z","record_hash":"e6def5e4d5ffbce0e596cbfc7c0523fa44fa1d59804af23051c81e3685f4685c","release_hash":"da6ed010b258737c4e5a9562823482a18159909d2e09f1cc3c53175a3349f05f","report_id":"erudio-nct06640166","run_id":"f0e123bd-de90-4e4c-9509-965399cbe807","schema_version":"5.0","slug":"eclypse-06640166","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"ECLYPse asks whether adding FOLFIRI while continuing encorafenib/cetuximab after progression benefits patients with BRAF V600E–mutant metastatic colorectal cancer. Practice-impact judgments in the sources reviewed for this edition range from an X poster’s description of a reasonable option to a medical oncologist’s emphatic endorsement. A physician favors continuation over rechallenge, while an X poster raises a mechanistic question. The biological explanation remains open in the discussion.","meta_description":"17 sources screened · 20 verified statements (12 from clinicians verified by NPI or staff page) from 7 sources · 4 findings. Updated Oct 29, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-9eb6223569684f8a10db","claim-9d687b26ec1a27839336"],"id":"F3","paraphrase":"X-thread questions address biological mechanism and whether continued treatment beyond progression is analogous to another treatment strategy.","publication_caveats":{"reason":"Publication caveats could not be established from the sources reviewed for this edition.","status":"unavailable"},"source_channel":"x_thread","source_date":"2026-10-24","title":"Continuation is favored over rechallenge by one speaker, but the mechanism remains a question"}]},"publication":{"approved_at":"2026-10-29T03:20:05Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":17},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","1 matching source (1 X thread) could not be read and is not included.","Not yet captured in this edition: a view on continuing targeted therapy beyond progression with chemotherapy and the need for more translational evidence.","Not yet captured in this edition: a view on continuing encorafenib plus cetuximab beyond progression with FOLFIRI and the need for more translational data.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","10 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","This report reflects the sources reviewed for this edition, not all public discussion or the prevalence of views among HCPs. Reposts should not be counted as independent endorsements.","One discussion could not be read, two potentially relevant passages were not fully assessed, and some additional comments could not be confidently attributed. Further qualifications or consequential views may therefore be absent.","No exact-trial results publication or protocol was available, and no regulatory label for the precise combination was identified. The commentary cannot establish approved use or independently resolve comparative benefit.","The reported treatment lines and six-month PFS percentages differ across sources and cannot be reconciled from the available statements.","The proof-of-concept sample and endpoint-evaluable denominator are small, OS is described as immature or not reached, and the reviewed commentary provides no tolerability assessment. Favorable efficacy interpretations should not be read as settled comparative or safety conclusions."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":6,"x_video":1,"youtube":0},"by_evidence_role":{"commentary":7},"count":7,"evidence_window":{"end":"2026-10-24","start":"2026-10-10"},"retrieval_snapshot":"2026-10-29T00:00:48.469720Z","timeline":[{"count":1,"week":"2026-W41"},{"count":7,"week":"2026-W43"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT06640166:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06640166:context","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1779173374071124269:9454f006-4af6-421e-9427-5fb6aca4ac56","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2108916269890392115:245932cc-b91e-4fcd-80bd-1bc11dac1376","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110627388082258023:e50ad5e5-b613-4b4a-837d-f67da8a41b33","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112106493612843011:7b8c3c52-25bf-4a8c-ab26-27a123d5c9e6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112107988689260587:564be1a1-10fb-41fe-9356-1952a7c23b0b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112984991609323557:9c223e09-5d05-453d-9fb5-230599c85c46","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113975866271420555:7108363e-5030-4615-ad63-5e0428cdda73","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113977841633386543:6706c432-e66f-417d-b965-ca4ef25e489b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113977989767557189:190d8772-c873-481f-aa07-80f839413700","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113979131083825513:94c1b1e1-0408-42b5-82b6-702e6b2d7877","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113979537688350830:0c2bcc00-d21c-4b48-a864-f4aadef5f73d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113982238069031254:70f0409c-2d68-4b61-a2be-e959a4c620cc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113983034202489120:8b787c3d-b33c-4dd7-b5bf-a119f956597e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113986074225660287:0552e2df-0d00-446b-8682-79cefe91435c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114059986376827300:ff44f0bd-d9e5-4f08-bed4-6396e1603748","quote_policy":"short_quote_link_out"},{"id":"mcp:x_video:2114059986376827300","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:ktT3SEiX7L4","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":15,"x_video":1,"youtube":1},"by_evidence_role":{"commentary":17},"count":17,"evidence_window":{"end":"2026-10-24","start":"2024-04-13"},"retrieval_snapshot":"2026-10-29T00:15:38.291100Z","timeline":[{"count":1,"week":"2024-W15"},{"count":1,"week":"2026-W19"},{"count":1,"week":"2026-W41"},{"count":1,"week":"2026-W42"},{"count":14,"week":"2026-W43"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: encorafenib + cetuximab + folfiri","status":"unmapped"}],"indications":[{"reason":"Unmapped registry condition: Colorectal Carcinoma","status":"unmapped"},{"reason":"Unmapped registry condition: Colorectal Neoplasms","status":"unmapped"},{"reason":"Unmapped registry condition: Colorectal Tumor","status":"unmapped"},{"reason":"Unmapped registry condition: Colorectal Adenocarcinoma","status":"unmapped"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Colorectal cancer","slug":"colorectal-cancer"},{"reason":"Unmapped registry condition: Colon Cancer","status":"unmapped"},{"reason":"Unmapped registry condition: Colon Adenocarcinoma","status":"unmapped"},{"reason":"Unmapped registry condition: Colon Carcinoma","status":"unmapped"},{"reason":"Unmapped registry condition: Colon Neoplasm","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"ECLYPse","aliases":["ECLYPse","Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.","Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab."],"brief_title":"Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.","collaborators":["Pierre Fabre Pharma GmbH"],"conditions":["Colorectal Carcinoma","Colorectal Neoplasms","Colorectal Tumor","Colorectal Adenocarcinoma","Colorectal Cancer (CRC)","Colorectal Cancer","Colon Cancer","Colon Adenocarcinoma","Colon Carcinoma","Colon Neoplasm"],"enrollment":{"count":25,"type":"ESTIMATED"},"interventions":[{"name":"encorafenib + cetuximab + FOLFIRI","synonyms":["encorafenib","cetuximab","FOLFIRI"],"type":"DRUG"}],"nct_id":"NCT06640166","official_title":"Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.","overall_status":"RECRUITING","phase":["PHASE2"],"primary_completion_date":{"date":"2025-12-31","type":"ESTIMATED"},"primary_endpoints":[{"description":"The proportion of patients alive and progression-free by the 6-month time point from start of investigational treatment (encorafenib plus cetuximab beyond progression in combination with FOLFIRI). Progression free survival is defined as the time elapsed between start of investigational treatment and the date of first event (progression or death, whichever occurs first).","measure":"6-month Progression Free Survival rate","timeFrame":"6 months after the enrollment of the last patient."}],"registry_last_updated":"2025-02-12","registry_url":"https://clinicaltrials.gov/study/NCT06640166","short_name":"ECLYPse","short_name_basis":"registry_acronym","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","start_date":{"date":"2024-06-03","type":"ACTUAL"},"study_design":"interventional, na, single group, phase2","study_ids":[{"id":"6070","type":"sponsor_study_id"},{"id":"2023-508615-24-00","type":"ctis"}],"study_type":"INTERVENTIONAL"}}}